Intravitreal ranibizumab (Lucentis) is currently one of the most widely used treatments for patients with centre involving diabetic retinopathy.

However, just like any other medication, some people respond better to this method of treatment than others.

The main objective of the Cytokine Trial is to identify patients who do and don’t respond to Lucentis and determine if markers within blood and aqueous (fluid within the eye) can predict this response.

This is a 12-month trial where patients will be followed up monthly. Lucentis is given on the first three visits, and subsequent treatment is determined based on whether or not stability has been reached for both visual acuity and the swelling at the back of the eyes.